GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Ending Cash Position

Pentixapharm Holding AG (XTER:PTP) Ending Cash Position : €11.92 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Pentixapharm Holding AG Ending Cash Position?

Pentixapharm Holding AG's Ending Cash Position for the quarter that ended in Jun. 2024 was €11.92 Mil.

Pentixapharm Holding AG's quarterly Ending Cash Position increased from Jun. 2023 (€7.70 Mil) to Dec. 2023 (€9.70 Mil) and increased from Dec. 2023 (€9.70 Mil) to Jun. 2024 (€11.92 Mil).

Pentixapharm Holding AG's annual Ending Cash Position declined from Dec. 2021 (€2.39 Mil) to Dec. 2022 (€1.09 Mil) but then increased from Dec. 2022 (€1.09 Mil) to Dec. 2023 (€9.70 Mil).

Pentixapharm Holding AG Ending Cash Position Historical Data

The historical data trend for Pentixapharm Holding AG's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pentixapharm Holding AG Ending Cash Position Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23
Ending Cash Position
2.39 1.09 9.70

Pentixapharm Holding AG Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24
Ending Cash Position - - 7.70 9.70 11.92

Pentixapharm Holding AG Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Pentixapharm Holding AG's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.086+8.615
=9.70

Pentixapharm Holding AG's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=9.701+2.217
=11.92

Pentixapharm Holding AG Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Pentixapharm Holding AG's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Pentixapharm Holding AG Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pentixapharm Holding AG (XTER:PTP) » Definitions » Ending Cash Position
Comparable Companies
STU:T9G XTER:HPHA XTER:MDG1 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX SMMT INSM HKSE:02269 BMRN RPRX XKRX:196170 OCSE:GMAB
Traded in Other Exchanges
PTPN:Austria
Address
Robert-Rossle-Street 10, Berlin, DEU
Website
https://www.pentixapharm.com
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic.

Pentixapharm Holding AG Headlines

No Headlines